Day One Biopharmaceuticals, Inc. (DAWN) News
Filter DAWN News Items
DAWN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DAWN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest DAWN News From Around the Web
Below are the latest news stories about DAY ONE BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate DAWN as an investment opportunity.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025. |
Are These AI Stocks Ready for a Comeback?Editor’s Note: My InvestorPlace colleague Luke Lango has been covering the two waves of the AI Revolution – the AI Builders and the AI Appliers – for the past few years. And readers of his research benefited tremendously after he spotted the AI Applier wave before it actually arrived. For example, Luke recommended top AI Applier stocks like Axon Enterprise Inc. (AXON) and AppLovin Corp. (APP) — now both up 350%-plus — before the crowd caught on. It’s why my other InvestorPlace colleague Eric Fry |
High Growth Tech Stocks to Watch in December 2024Over the last 7 days, the United States market has dropped by 2.7%, yet it has risen by an impressive 23% over the past year, with earnings forecasted to grow by 15% annually. In this context of robust annual growth despite recent fluctuations, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a dynamic market environment. |
Day One to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. A live audio webcast |
How Trump Can Help Crypto on Day OneA simple executive order issued on Jan. 20 would pave the way for the crypto sector’s resurgence in the U.S. |
Instagram locks out developers of third-party consumer appsA change to Meta's developer tools is impacting third-party consumer apps that had previously integrated with Instagram. Among those affected by the changes are the Match-owned dating apps Tinder and Hinge, which had allowed their users to link their Instagram profiles to their accounts to display their posts to potential matches. Day One, the journaling app that WordPress.com owner Automattic bought in 2021, is also losing a key piece of its functionality because of the change. The company anno |
Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) stands against the other up and coming stocks. Donald Trump’s victory in the recent presidential election is expected to encourage companies […] |
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & DevelopmentDr. Blackman’s departure planned for end of 2024 Company’s search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be |
Day One to Participate in the Piper Sandler 36th Annual Healthcare ConferenceBRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 3:00 p.m. EST. A live webcast of the discussion will be available by visiti |
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |